Sartorius Stedim Biotech Reports Half-Year Liquidity Statement

Sartorius Stedim Biotech ( (FR:DIM) ) has issued an update.

Sartorius Stedim Biotech’s half-year liquidity contract statement with Kepler Cheuvreux reflects a stable but slightly decreased liquidity position as of December 31, 2024, compared to the previous semester. The report, executed in compliance with AMF Decision N°2021 -01, indicates the company’s active engagement in market practices, with significant trading volumes on both the buy and sell sides, reflecting ongoing operational activities and strategic financial management.

More about Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner in the biopharmaceutical industry, headquartered in Aubagne, France. The company provides innovative solutions for the safe, rapid, and economical manufacture of biotech medications, including cell and gene therapies. With a strong global presence, Sartorius Stedim Biotech has manufacturing, R&D sites, and sales entities across Europe, North America, and Asia, and its shares are quoted on Euronext Paris. In 2023, the company achieved sales revenue of approximately 2.8 billion euros and employs over 10,600 people worldwide.

YTD Price Performance: -3.45%

Average Trading Volume: 30,530

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €17.64B

See more insights into DIM stock on TipRanks’ Stock Analysis page.